Učitavanje...
Sunitinib re-challenge in advanced renal-cell carcinoma
Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the effectiveness of targeted therapies eventually declines with the development of resistance. Defining optimal sequences of therapy is therefore the focus of much current research. There is also evidence that tr...
Spremljeno u:
| Izdano u: | Br J Cancer |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4453836/ https://ncbi.nlm.nih.gov/pubmed/24800947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.214 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|